| Product | Primary Uses | Product Description |
| FLEXBUMIN 25%, Albumin (Human) |
Plasma-volume replacement therapy for the treatment of hypovolemia Please see Important Risk Information Please see full Prescribing Information |
A sterile, nonpyrogenic preparation of albumin in a single-dosage form for intravenous administration |
|
BUMINATE 25% Albumin (Human) and BUMINATE 5% Albumin (Human) |
Plasma-volume replacement therapy for the treatment of hypovolemia Please see Important Risk Information Please see full Prescribing Information (5%) Please see full Prescribing Information (25%) |
A sterile, nonpyrogenic preparation of albumin in a single-dosage form for intravenous administration |
| CEPROTIN [Protein C Concentrate (Human)] |
For patients with severe congenital Protein C deficiency for the prevention and treatment of:
For pediatric and adult use Please see Important Risk Information Please see full Prescribing Information |
500 IU (5ml of SWFI) or 1000IU (10ml of SWFI) vial of CEPROTIN powder, one vial of Sterile Water for Injection (diluent) |
For additional resources, please click here.
During traumatic events where blood loss can be high, such as a car accident or surgery, patients receive albumin to help restore their blood volume. Albumin is derived from blood plasma collected at collection centers across the US, such as Baxter’s BioLife Plasma Services centers. Baxter's FLEXBUMIN therapy is the first and only albumin in a flexible plastic container. Unlike glass containers, FLEXBUMIN is easier to transport and store, and won't break.1
During traumatic events where blood loss can be high, such as a car accident or surgery, patients receive albumin to help restore their blood volume.3, 4 Albumin is derived from blood plasma collected at collection centers across the U.S., such as Baxter’s BioLife Plasma Services centers.
For more information on FLEXBUMIN therapy and BUMINATE therapy, please visit www.albumintherapy.com
FLEXBUMIN 25% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. FLEXBUMIN 25% is indicated in hypovolemia, hypoalbuminemia due to inadequate production, excessive catabolism, hemorrhage, major surgery or burns, and for use during cardiopulmonary bypass surgery.
CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.
Please see full Prescribing Information
BUMINATE 5% Albumin (Human), USP, 5% Solution is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.
BUMINATE 25% Albumin (Human), USP, 25% Solution is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.
Please see full Prescribing Information (5%)
Please see full Prescribing Information (25%)
Fewer than 20 known patients in the United States have been diagnosed with severe congenital Protein C deficiency.This rare disease presents with life threatening blood clots that may affect multiple organs such as the skin, kidneys and brain. CEPROTIN therapy allows the body's blood clotting process to function properly. On March 30, 2007, the FDA approved CEPROTIN therapy for orphan drug status. [BAXTER PR]
For more information, please visit our Web site at www.ceprotin.com.
CEPROTIN [Protein C Concentrate (Human)] is used for patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis (blood clot in the vein), and purpura fulminans (blood spots, bruising and discoloring to skin as a result of clotting of small blood vessels in the skin). CEPROTIN is indicated as a replacement therapy for pediatric and adult patients.
CEPROTIN contains small amounts of heparin and/or mouse protein as a result of the manufacturing process. If you are known to have allergic-type reactions (rash, hives, itching, tightness of the chest, difficulty breathing, throat tightness, and low blood pressure) to mouse protein or to heparin, you should talk to your doctor before using this product. If you experience a severe allergic reaction, including difficulty breathing and (near) fainting while being treated with CEPROTIN, you should quickly seek emergency treatment.
CEPROTIN is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD)agent.
CEPROTIN contains trace amounts of heparin that may lead to Heparin-induced Thrombocytopenia (a low platelet count which could result in increased bleeding).
Patients on a low salt diet or who have kidney problems should be aware thatthe quantity of salt in the maximum daily dose of CEPROTIN exceeds 200 mg.
The most serious and common side effects to CEPROTIN observed in clinical trials were rash, itching and lightheadedness. There have also been individual reports, after the drug was approved, of bleeding into the chest, very low blood pressure, fever, restlessness and increased sweating.
A sterile, nonpyrogenic preparation of albumin in a single-dosage
